Thursday, and MedTech is not having a quiet week. A geopolitical cyberattack hit one of the biggest names in surgical equipment, wiping out core IT systems. Boston Scientific is quietly building out a second urology platform through a new acquisition. A small spinal device maker raised bridge financing. And Baxter's CFO is stepping down after helping lead one of the company's most significant restructurings in years. Here's Issue #4, let's get into it.
Top Stories
Story 01
Reports confirmed this week that an Iranian-backed “hacktivist” group launched a destructive wiper attack against Stryker Corporation, targeting the company's Microsoft-based IT systems and effectively destroying data so it cannot be retrieved. The group cited U.S. and Israeli military actions beginning February 28 as justification. Stryker confirmed the incident is disrupting order processing, manufacturing, and shipping operations across multiple divisions. Forensic experts have been engaged. No patient data breach has been confirmed.
Why This Matters
Wiper attacks are worse than ransomware: there's nothing to recover, nothing to pay for. Stryker runs distributed manufacturing across 40+ plants globally, and disrupting order processing affects hospital procurement cycles directly. Every MedTech manufacturer still running on-premise Windows infrastructure needs air-gapped backups and a tested incident response plan. This is a patient safety issue, not just an IT one.
Cybersecurity
Critical Infrastructure
Story 02
Boston Scientific announced in January an agreement to acquire Valencia Technologies, the maker of the FDA-approved eCoin System for urge urinary incontinence. The eCoin is a coin-sized implantable device placed near the ankle that uses low-level tibial nerve stimulation to regulate communication between the brain and bladder. In clinical trials, 68% of patients saw at least a 50% reduction in incontinence episodes. The deal gives Boston Scientific a direct competitor to Medtronic's Altaviva tibial stimulation device, building out a full pelvic health platform alongside its existing Axonics sacral neuromodulation system. Expected to close in the first half of 2026.
Acquisition
FDA-Approved
Story 03
Tenon Medical completed a $4.3 million senior OID (original issue discount) convertible note offering to fund ongoing clinical work on its sacroiliac joint fusion system. Tenon's device addresses SI joint dysfunction, a source of chronic low back pain that is increasingly recognized as underdiagnosed. The notes mature in September 2026, giving the company a near-term runway to advance its FDA registration trial. Small but meaningful progress in the SI joint space, which has seen growing interest from spine surgeons.
$4.3M
Clinical Stage
Story 04
Baxter International announced the departure of CFO Joel Grade, who is leaving to prioritize family matters after a tenure defined by one of the most significant portfolio reshapings in Baxter's history, including the divestiture of its kidney care unit, Vantive, to a private equity buyer. CEO Andrew Hider praised Grade's contributions through the transformation. Anita Zielinski, who joined Baxter in 2025 as chief accounting officer and controller, has been named interim CFO while the company conducts its search for a permanent replacement. Grade will remain in an advisory capacity through April 30, 2026.
Leadership
Restructuring
Know someone in MedTech? Forward this to a colleague. It only takes 5 minutes and saves them from missing the week's biggest moves.
Market Movers
| Ticker | Company | Price | Wk Change |
|---|
| ISRG | Intuitive Surgical | $518.60 | ▼ 0.8% |
| SYK ★ | Stryker | $341.80 | ▼ 4.6% |
| BDX | BD (Becton Dickinson) | $232.50 | ▼ 1.2% |
| JNJ | Johnson & Johnson | $157.90 | ▲ 0.7% |
| ABT | Abbott | $139.40 | ▼ 0.9% |
| ZBH | Zimmer Biomet | $107.20 | ▼ 1.4% |
| BSX | Boston Scientific | $104.20 | ▼ 0.9% |
| GEHC | GE HealthCare | $92.10 | ▼ 1.2% |
| MDT | Medtronic | $90.10 | ▲ 0.9% |
| EW | Edwards Lifesciences | $70.80 | ▲ 1.0% |
★ Top Mover of the week (biggest % change). Sorted by stock price, highest to lowest. Data shown for illustrative purposes. Prices reflect approximate close, week of March 12, 2026.
Deep Dive
Why 2026 Is a Banner Year for MedTech M&A, And What Comes Next
The MedTech M&A market in 2026 has started with more activity than any year since 2021. Boston Scientific's $14.5B Penumbra deal, Danaher's Masimo acquisition, Haemonetics acquiring Vivasure, Laborie taking the JADA System from Organon, we've had four significant transactions in the first two and a half months of the year. Here's why it's happening and what the pattern tells us.
- Large-cap MedTech is cleaning up its portfolios. Companies like Medtronic, Baxter, and J&J have spent the last two years divesting non-core businesses. That's created capital for targeted acquisitions in high-growth segments, cardiac ablation, vascular intervention, surgical robotics, and maternal health. Companies are narrowing to win in fewer categories rather than competing everywhere.
- The acquirers have pricing power right now. Rising interest rates made big deals more expensive in 2023–2024. With rates stabilizing and strategic buyers sitting on strong balance sheets, the math works better in 2026. Sellers who held out through the lean years are now getting deals done at valuations they're comfortable with.
- Small-cap targets are looking attractive after a rough two years. Many high-growth MedTech companies that went public in 2020–2021 are now trading significantly below their IPO prices. That gap between public market valuations and strategic value is where M&A happens. Expect continued activity in neurovascular, cardiac monitoring, and orthopedic robotics.
Bottom line: The 2026 M&A wave isn't random, it's the result of two years of portfolio cleanup meeting a more favorable financing environment. Companies that built clean, focused businesses with strong clinical data are the likeliest acquisition targets. The activity won't stop before summer.
Industry Shifts
Shift 01
The Boston Scientific-Penumbra deal announced in January is progressing through regulatory and shareholder approvals, with BSX CEO Mike Mahoney indicating a second-half 2026 close is the target. The deal brings Penumbra's Lightning thrombectomy system, a computer-assisted vacuum device for rapidly removing blood clots, into Boston Scientific's cardiovascular portfolio. Mahoney noted that the combination strengthens BSX's relationships with vascular surgeons, a physician group where it previously had limited reach.
M&A Update
Shift 02
Following the first U.S. soft-tissue surgery cases at Cleveland Clinic, Medtronic is accelerating the commercial rollout of its Hugo robotic surgery system. The company is targeting high-volume academic medical centers and integrated health systems for early adoption, leveraging Hugo's open-architecture design and competitive pricing as differentiation against Intuitive Surgical's da Vinci. Hugo's initial U.S. indication covers urological procedures, with additional surgical indications expected through 2026.
Surgical Robotics
Commercial Launch
Fun Fact & Trivia
Fun Fact
Minnesota is home to more medical device companies per capita than any other U.S. state, earning its nickname “Medical Alley.” The corridor running through Minneapolis–St. Paul hosts Medtronic, Abbott's vascular and cardiac divisions, Boston Scientific's cardiac rhythm management unit, and hundreds of smaller device makers. More than 5,000 medical technology companies and organizations operate in the state, generating over $25 billion in annual economic output, according to the Medical Alley Association. (Source: Medical Alley Association)
MedTech Trivia
Which U.S. company made the first commercially successful defibrillator cleared for hospital use?
👇 Scroll to the footer for the answer
Sponsor
